Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP for Skin Graft Donor Site Wounds
NCT04664738Phase 1Unknown
- Sponsor
- RION
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of platelet-derived exosome product in skin graft donor-site wound (SGDW) (3 arms), sponsored by RION. Primary endpoints: Acute Dose Limiting Toxicities at 2 weeks and Maximum Tolerated Dose at 2 weeks. Status: unknown.
02
Drugs
platelet-derived exosome product
03
Conditions
skin graft donor-site wound (SGDW)
Beyond the preview
Go deeper on NCT04664738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664738.